These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6134517)

  • 61. A study of clinical response to different kinds of neuroleptics in first time medicated schizophrenics.
    Kadota K
    Jpn J Psychiatry Neurol; 1992 Mar; 46(1):127-53. PubMed ID: 1353124
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A study on the acute effect of amphetamine on the urinary excretion of biogenic amines and metabolites in monkeys.
    Chuang LW; Karoum F; Perlow MJ
    Br J Pharmacol; 1981 Nov; 74(3):571-7. PubMed ID: 7296162
    [TBL] [Abstract][Full Text] [Related]  

  • 63. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.
    Nemeroff CB; Bissette G; Widerlov E; Beckmann H; Gerner R; Manberg PJ; Lindstrom L; Prange AJ; Gattaz WF
    J Neuropsychiatry Clin Neurosci; 1989; 1(1):16-20. PubMed ID: 2577718
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia.
    Sasayama D; Hattori K; Teraishi T; Hori H; Ota M; Yoshida S; Arima K; Higuchi T; Amano N; Kunugi H
    Schizophr Res; 2012 Aug; 139(1-3):201-6. PubMed ID: 22742979
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.
    Gattaz WF; Köllisch M; Thuren T; Virtanen JA; Kinnunen PK
    Biol Psychiatry; 1987 Apr; 22(4):421-6. PubMed ID: 3567258
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables.
    Buckman TD; Kling A; Sutphin MS; Steinberg A; Eiduson S
    Psychiatry Res; 1990 Jan; 31(1):1-14. PubMed ID: 1969170
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical subtypes of schizophrenia: differences in brain and CSF volume.
    Gur RE; Mozley PD; Shtasel DL; Cannon TD; Gallacher F; Turetsky B; Grossman R; Gur RC
    Am J Psychiatry; 1994 Mar; 151(3):343-50. PubMed ID: 8109642
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neuroleptic drug effects on cognitive function in schizophrenia.
    Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM
    Schizophr Res; 1990; 3(3):211-9. PubMed ID: 1980613
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Predictors of outcome in schizophrenia: the process-reactive dimension.
    Harrow M; Westermeyer JF; Silverstein M; Strauss BS; Cohler BJ
    Schizophr Bull; 1986; 12(2):195-207. PubMed ID: 2872722
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients.
    Gattaz WF; Riederer P; Reynolds GP; Gattaz D; Beckmann H
    Psychiatry Res; 1983 Apr; 8(4):243-50. PubMed ID: 6576391
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
    Banki CM; Arató M
    Acta Psychiatr Scand; 1983 Apr; 67(4):272-80. PubMed ID: 6190356
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics.
    Pakkenberg B
    Schizophr Res; 1992 Jul; 7(2):95-100. PubMed ID: 1355358
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increased blink rate in drug-naive acute schizophrenic patients.
    Mackert A; Woyth C; Flechtner KM; Volz HP
    Biol Psychiatry; 1990 Jun; 27(11):1197-202. PubMed ID: 2354226
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A study of thought disorder in paranoid and non-paranoid schizophrenia.
    Mazumdar PK; Chaturvedi SK; Gopinath PS
    Psychopathology; 1991; 24(3):166-9. PubMed ID: 1754647
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
    Linnoila M; Ninan PT; Scheinin M; Waters RN; Chang WH; Bartko J; van Kammen DP
    Arch Gen Psychiatry; 1983 Dec; 40(12):1290-4. PubMed ID: 6197036
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cell-Based Biosensor with Dual Signal Outputs for Simultaneous Quantification of Phenylacetic Acid and Phenylethylamine.
    Guo KH; Lu KH; Yeh YC
    ACS Synth Biol; 2018 Dec; 7(12):2790-2795. PubMed ID: 30418753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Distractibility and recall capability in schizophrenics. A 4 year longitudinal study of stability in cognitive performance.
    Rund BR
    Schizophr Res; 1989; 2(3):265-75. PubMed ID: 2487167
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Increased serum phospholipase A2 activity in schizophrenia: a replication study.
    Gattaz WF; Hübner CV; Nevalainen TJ; Thuren T; Kinnunen PK
    Biol Psychiatry; 1990 Sep; 28(6):495-501. PubMed ID: 2223919
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
    Sedvall GC; Wode-Helgodt B
    Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.